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Objectives. Yhis study was designed to prospectively evaluate 
the long-term outcome of drug therapy guided by head-up tilt 
testing for the management of unexplained syncope and near 
syncope. 
Background. Head-up tilt testing is used to evaluate patients 
with unexplained syncope. The validity of acute drug testing and 
the efficacy of long-term oral therapy for prevention of recurrent 
syncope have not been investigated in large patient groups. 
Methods. We studied 296 consecutive patients with unexplained 
syncope or near syncope who underwent 80 ° head-up tilt testing 
with and without isoproterenol challenge. The efficacy of intrave- 
nous and oral beta-blocker therapy was evaluated by repeat 
testing. Patients with both positive and negative responses to 
therapy were followed up for rates of recurrence of syncope. 
Results. A total of 193 patients (65%) had a positive tilt test 
response; 89% of these 193 required isoproterenol challenge to 
elicit this response. Patients with a positive tilt test result had 
lower values for heart rate at rest (mean _+ SD 69 -+ 13 vs. 74 -+ 
14 beats/min, p = 0.046) and systolic blood pressure (137 -+ 28 vs. 
145 -+ 30 mm Hg, p = 0.0018) at baseline than did the patients 
with a negative tilt test result. Intravenous propranolol blocked 
the positive response in 163 (90%) of 181 patients retested. Oral 
beta-blockers were effective by tilt test criteria in 118 (94%) of 125 
patients; 12 (10%) had recurrent clinical symptoms while taking 
beta-blockers. Eight (42%) of 19 patients who had a negative tilt 
test response during beta-blocker therapy had recurrent symp- 
toms when they stopped therapy. Three (23%) of 13 patients 
receiving empiric beta-blocker therapy had recurrent symptoms. 
The follow-up eriod for the patients with a positive tilt test result 
was 28 +- 11 months (range 5 to 48). 
Conclusions. Intravenous propranolol is effective in preventing 
neurocardiogenic syncope diagnosed uring head-up tilt testing 
and predicts the response to oral beta-blocker therapy. Oral 
beta-blocker therapy prevents recurrent syncope in the majority of 
patients. Recurrence of syncope is lowest when efficacy of oral 
beta-blocker therapy is confirmed by repeat head-up tilt testing. 
(J Am Coil Cardiol 1995;26:1293-8) 
Syncope is a common clinical problem with multiple causes 
and mechanisms that have been incompletely understood (1). 
Recently, the development of head-up tilt testing has provided 
a method for studying the mechanisms, clarifying the diagnosis 
and evaluating treatment ofneurocardiogenic syncope, or what 
was formerly described as vasovagal or vasodepressor syncope 
(2-6). The triggering event for an episode of neurocardiogenic 
syncope is thought to be an increase in adrenergic tone 
resulting in activation of cardiopulmona~; mechanoreceptors 
that may overwhelm or reverse normal compensatory mecha- 
nisms and result in paradoxic hypotension, bradycardia, or 
both. Therefore, the rationale for the use of beta-adrenergic 
blocking agents is to block the initial increase in adrenergic 
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tone and thus interrupt he cascade of inappropriate and 
exaggerated neurocardiac nd peripheral vascular adjustments 
that lead to syncope. Two cardioselective beta-adrenergic 
blockers, intravenous metoprolol (5) and intravenous esmolol 
(7), have been shown to block the reflex responsible for 
neurocardiogenic syncope when they are given during head-up 
tilt testing. However, limited data are available on the long- 
term efficacy of oral beta-blocker therapy in patients with 
ncurocardiogenic syncope. To date, there are reports provid- 
ing follow-up data on a total of 207 patients followed up for 6 
to 28 months. Recurrence rates of syncope have ranged from 
6';~ to 28% in patients treated with beta-blockers (2,5,8-11). 
This study was designed 1) to evaluate a large group of 
patients with unexplained syncope by using head-up tilt testing 
as the primary diagnostic method, and 2) to assess the etficacy 
of beta-blocker therapy for preventing neurocardiogenic syn- 
cope both immediately (intravenous propranolol during 
head-up tilt testing) and in the long term (oral cardioselective 
or nonselective beta-blocker therapy). In addition, to estimate 
specificity of the procedure and therapy, we analyzed recur- 
rence rates of syncope in patients who responded to beta- 
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Table 1. Patient Characteristics 
Head-Up Tilt Test Response 
Positive Negative 
(n - 193) (n = 103) p Value 
Age (yr) 53 _+ 20 59 ÷ 20 0.015 
Male/female ratio (%) 51/49 54/46 NS 
Episodes of syncope 
0, near syncope only 47 (24%) 27 (26%) 
1 24(12%) 20(19%) 
2 18 (9%) 14 (13%) 
3 or more 104 (54%) 42 (41%) 
Normal ejection fraction 183 (95%) 89 (87%) 0.01 
Mitral valve prolapse 28 (15%) 11 (10%) NS 
Hypertension 21 (11%) 28 (27%) NS 
Coronary artery disease 28 (12%) 18 (17%) NS 
Unless otherwise indicated, data are expressed as mean value _+ SD or 
number (%) of patients. 
blocker therapy but did not continue it and in patients who had 
a negative response on initial head-up tilt tests. 
Methods  
Patients. A cohort of 296 consecutive patients referred for 
evaluation of unexplained syncope or near syncope from 1990 
to 1994 were included in this study. All patients underwent a 
complete history and physical examination, routine blood 
studies to rule out anemia or electrolyte imbalances, a standard 
12-lead electrocardiogram (ECG) and neurologic evaluation, 
including a computed tomographic s an or magnetic resonance 
imaging of the brain, as well as an electroencephalogram and 
carotid artery Doppler studies when deemed appropriate. 
Head-up tilt testing. All patients underwent tilt testing in a 
fasting, nonsedated state after giving written informed consent. 
All received aminimum of 500 ml of normal saline or lactated 
Ringer solution intravenously before the test to ensure that 
they were euvolemic. Patients were placed in a supine position 
on an electronically controlled tilt table with a foot board for 
weight bearing, and baseline blood pressure and pulse were 
recorded after a 5-rain equilibration period. Blood pressure 
was measured by an automatic sphygmomanometer andby a 
manual mercury sphygmomanometer when the blood pressure 
could not be obtained automatically. Heart rate and rhythm 
were recorded with the use of a three-lead ECG. After 
baseline blood pressure and heart rate were recorded, the 
patients were tilted to an 80 ° angle for a maximum of 10 min, 
or less if the patient became symptomatic. Blood pressure and 
heart rate were recorded every minute. A positive test result 
was defined as syncope, near syncope or extreme light- 
headedness associated with hypotension or bradycardia, or 
both. Patients who remained asymptomatic during the baseline 
tilt were returned to the supine position and given an isopro- 
terenol infusion in gradually increasing doses to a maximum of 
5/zg/min. An equilibration period of 5 rain was allowed after 
each increase in isoproterenol dose. 
Intravenous drug testing. Patients with a positive test 
response were returned to the supine position and allowed to 
recover. After a minimum of 5 rain for equilibration and 
stabilization, they were given intravenous propranolol in incre- 
ments of 1 to 2 mg/min to a total dose of 0.2 mg/kg total body 
weight. After the infusion of propranolol was completed, the 
patients underwent repeat ilt testing under the same condi- 
tions in which the initial positive test result was elicited. 
Oral drug testing. Patients with a positive tilt test result 
and a beneficial response to intravenous propranolol were 
started on treatment with either short-acting propranolol, 
atenolol, metoprolol or nadolol and the dose was titrated to 
achieve clinical beta-blockade. The choice of oral beta-blocker 
therapy was not randomized. Once beta-adrenergic blockade 
was achieved, patients underwent a repeat ilt test at baseline 
with no isoproterenol stimulation; if isoproterenol had been 
required during the initial study, they also underwent an 
additional tilt test performed with the same dose of isoproter- 
enol that had resulted in the initial positive test result. 
Follow-up. During follow-up, each patient was contacted 
by telephone very 3 months, or was seen during regularly 
scheduled follow-up visits, to evaluate clinical status, including 
recurrent symptoms and compliance with prescribed beta- 
blocker therapy. Recurrence of symptoms was defined as 
syncope or near syncope. 
Statistical analysis. The Student test was used to com- 
pare results within groups (paired) and among groups (un- 
paired). Chi-square analysis was used to compare groups when 
variables were dichotomous. 
Resul ts  
Study group characteristics. Among the 296 patients with 
unexplained syncope or near syncope who underwent head-up 
tilt testing, 193 (65%) had a positive and 103 had a negative 
test result (Table 1). Patients with a positive result were 
younger than patients with a negative result (mean _+ SD 53 + 
20 vs. 59 _+ 20 years, p = 0.015). The proportion of men and 
women in each group was similar, as was the distribution of the 
number of syncopal episodes. Ninety-five percent of patients 
with a positive tilt test result had a normal ejection fraction 
compared with 87% of patients with a negative result (p -- 
0.01). There were no significant differences between the pa- 
tients with a positive and a negative test result with respect to 
the presence of mitral valve prolapse, hypertension r coronary 
artery disease. 
Initial hemodynamic findings. Patients with a positive tilt 
test result had a lower baseline heart rate at rest (69 _+ 13 vs. 
74 ± 14 beats/rain, p = 0.046) and systolic blood pressure at 
rest (137 ± 28 vs. 145 ± 30 mm Hg (p = 0.0018) than did 
patients with a negative test result. When subgrouped by 
gender, there was no significant age difference between women 
with a positive or negative test result or between men with a 
positive or a negative test result. However, men in both the 
positive and negative test result groups were older and had a 
higher est systolic blood pressure than that of women. 
JACC Vol. 26, No. 5 COX ET AL. 1295 
November 1, 1995:1293-8 BETA-BLOCKADE FOR NEUROCARDIOGENIC SYNCOPE 
Table 2. Hemodynamic Response to Oral Beta-Blocker Therapy 
Dose 
Patients Range Before 
Drug (no.) (mg/day) Drug 
Systolic Blood Pressure (mm Hg) Heart Rate (beats/min) 
After p Before After p 
Drug Value Drug Drug Value 
Atenolol 78 25-100 131 ±28 
Propranolol 28 40-240 149 ± 26 
Metoprolol 16 50-2~) 135 ~ 29 
Nadolol 3 40-320 131 • 13 
126 _+ 28 0.0047 67 _+ 12 55 -_+ 8 0.0001 
135 _+ 29 < 0.0036 75 _+ 12 61 _+ 7 < 0.0001 
123 _+ 18 0.018 74 _+ 12 61 _+ 11 0.002 
134 +_ 21 NS 63 _+ 12 46 _+ 6 0.08 
Unless otherwise indicated, data are expressed as mean value _+ SD. 
Response patterns during initial tilt tests. Among the 193 
patients with a positive tilt test result, 144 patients (75%) had 
a mixed vasodepressor and cardioinhibitory esponse with both 
hypotension and bradycardia, and 49 patients (25%) had a 
pure vasodepressor response during tilt testing. No patient had 
a pure cardioinhibitory response. The patients with a pure 
vasodepressor response were significantly older than patients 
with a mixed response (63 _+ 16 vs. 49 + 20 years, p < 0.0001). 
Twenty-one patients (11%) had a positive tilt test result at 
baseline without isoproterenol challenge. Sixty-seven patients 
(35%) required up to 2/xg/min of intravenous i oproterenol to
elicit a positive test result and the remaining 105 patients 
(54%) required 3 to 5/zg/min of isoproterenol. 
Response to therapy. Data were analyzed for response to 
intravenous propranolol during the initial tilt test and to oral 
therapy with propranolol, atenolol, metoprolol and nadolol 
during a second tilt test. 
Response to intravenous propranolol. Among the 193 pa- 
tients who had a positive initial head-up tilt test result, 181 
received intravenous propranolol. Of these, 163 (90%) had a 
negative head-up tilt test result during repeat testing after 
propranolol administration. Eighteen patients continued to 
have a positive tilt test result after intravenous propranolol. 
Two of the 18 had prolonged asystole (19 and 30 s, respec- 
tively) during repeat ilt testing after intravenous propranolol; 
neither had this response during the initial tilt test before 
administration of propranolol or experienced it clinically. 
Response to oral beta-blockers. Among the 163 patients who 
had a negative tilt test result after intravenous propranolol, 157 
were treated with oral beta-blockers (atenolol in 98, proprano- 
lol in 33, metoprolol in 22 and nadolol in 4). All oral 
beta-blockers except nadolol significantly decreased the rest 
values for systolic blood pressure and heart rate from pre-drug 
values (Table 2). One hundred eighteen patients underwent 
repeat esting while receiving oral therapy, and drug efficacy in 
this group ranged from 91% to 100% (Table 3). Although 
atenolol was slightly less efficacious than the other agents, this 
difference was not statistically significant. Three of the 18 
patients who did not respond favorably to intravenous pro- 
pranolol (excluding the two patients with prolonged asystole) 
underwent permanent pacemaker implantation to provide 
pacing back-up for beta-blocker-induced symptomatic brady- 
cardia. After pacemaker implantation the patients were given 
oral propranolol, 80 to 240 mg daily in divided doses, and had 
a negative result on repeat head-up tilt testing. One patient 
who did not respond favorably to intravenous propranolol was 
given oral propranolol, 40 mg every 6 h, and had a negative 
response during repeat testing. Seven patients continued to 
have a positive head-up tilt test result while taking oral 
atenolol despite adequate beta-blockade; six of these seven 
were retested with another beta-blocker (propranolol in five 
and metoprolol in one) and had a negative repeat tilt test 
result. 
Follow-up: recurrence of symptoms. Patients with both 
positive and negative initial tilt test results were contacted to 
evaluate long-term outcome and rates of recurrence of syncope 
in both groups. Recurrence of symptoms (syncope or near 
syncope) was analyzed with respect to patient age and gender, 
number of syncopal episodes, presenting symptoms, ejection 
fraction, underlying heart disease, hemodynamic response 
during tilt testing, use of isoproterenol during the initial test 
and type of beta-blocker therapy used. Recurrence of syrup- 
Table 3. Tilt Test Results: Oral Beta-Blocker Therapy 
Patients (no.) Patients Continuing Patients Discontinuing Patients Receiving 
With Neg With Pos Tilt-Proved Therapy Tilt-Proved Therapy Empiric Therapy 
Tilt Test Tilt Test Not Drug With With With 
Drug Total Response Response Tested Etficacy* No. Recurrence# No. Recurrencet No. Recurrencet 
Atenolol 98 71 7 20 91% 71 8 (11%) 10 4 (40%) 7 1 (14%) 
Propranolol 33 28 (I 5 100% 28 2 (7%) 5 3 (60%) 2 l (50%) 
Metoprolol 22 16 !1 6 100% 16 0 (0%) 4 1 (25%) 3 1 (33%) 
Nadalol 4 3 il 1 100% 3 2 (67%) 0 0 (0%) 1 0 (0%) 
Total 157 118 7 32 94% 118 12 (10%) 19 8 (42%) 13 3 (23%) 
*Determined as{(-)T/[(-)T + (+)T]} × 100, where (-)T = negative (Neg) tilt test, and (+)T = positive (Pos) tilt test. tOf syncope or near syncope. Unless 
otherwise indicated, data are expressed as number (%) of patients. 
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Figure 1. Actuarial probability offreedom from recurrent 
symptoms ( yncope or near syncope) among patients 
whose initially positive tilt test result was followed by a 
negative r sult during treatment with oral beta-adrenergic 
blocking agents. Curve A represents experience in patients 
who continued beta-blocker therapy; curve B represents 
those who discontinued therapy. The difference between 
the two groups was significant (p< 0.0009). 
toms was independent of all these variables except with respect 
to the beta-blocker nadolol. However, only three patients 
received nadolol and were retested; a larger sample size is 
needed to make an accurate assessment of the effect of this 
beta-blocker. Among patients who used beta-blocker therapy 
proved effective by tilt testing, only 10% had recurrent symp- 
toms during a mean follow-up interval of 28 + 11 months. In 
contrast, empiric beta-blocker therapy resulted in a 23~ 
recurrence rate, whereas patients who discontinued beta- 
blocker therapy that had been proved effective had a 42% 
recurrence rate. Patients who had a positive tilt test result but 
remained untreated had a 58% recurrence rate. 
We analyzed the symptoms and drug compliance history in 
the 12 patients (10% of 118) who had recurrent symptoms 
despite drug efficacy-proved bytilt testing. Five of these 12 had 
been partially non-compliant, decreasing the dose of medica- 
tion that had resulted in a negative repeat ilt test result. The 
other seven patients had required multiple medication trials to 
find a therapeutic regimen that would prevent their symptoms. 
The actuarial rate of freedom from recurrent syncope was 93el 
at 3 months, 92% at 6 months and 90% at i year in the patients 
who continued the drug therapy proved effective by tilt testing 
(Fig. 1). 
Eight of 19 patients who discontinued tilt-proved effective 
therapy had recurrent symptoms. Thus, patients who discon- 
tinued beta-blocker therapy that was confirmed to be effective 
by repeat ilt testing had a significantly higher ate of recurrent 
syncope than did patients who continued beta-blocker therapy 
(42% vs. 10%, p = 0.0009). Recurrence was independent of
whether or not isoproterenol had been required to evoke a 
positive test result. 
Two patients died; one of unknown causes 12 months after 
the second tilt test and one of a myocardial infarction 34 
months after the second tilt test. Both had been taking their 
prescribed medication. The mean time of follow-up for all 
patients was 28 _+ 11 months (range 5 to 48). Thirty-five 
patients were lost to follow-up. 
Patients with an initial negative tilt test result. Among the 103 
patients who initially had a negative tilt test result, 4 died of 
unknown causes and 36 were lost to follow-up. The remaining 
67 patients were followed up a mean of 25 _+ 12 months (range 
6 to 52). Eleven (16%) of the 67 had recurrent syncope or near 
syncope: 2 with ventricular tachycardia, 1 with a pacemaker 
and hypertension, 1 with epilepsy, 1with a conversion disorder, 
1 with an aortic valve replacement and 1 with chronic obstruc- 
tive pulmonary disease. One patient had syncope only in 
association with extreme pain. Three patients were given 
therapy for presumed neurocardiogenic syncope (beta- 
blockers in two, aminophylline in one) in the absence of a 
positive tilt test result. Of the 38 asymptomatic patients, 18 had 
subsequently received therapy prescribed by other physicians 
for various indications. Nine (24%) had permanent pacemak- 
ers for bradycardia indications, two were receiving beta- 
blockers, three oral aminophylline, two fludrocortisone, one 
ephedrine and one meclizine. Although the incidence of 
recurrent syncope tended to be greater among the patients 
who had an initial negative tilt test result than among those 
with an initial positive test result who were effectively treated 
with beta-blockers (16% vs. 10%), the rate of recurrent 
syncope was not significantly different between the two groups. 
Discussion 
Head-up tilt testing has become a widely used diagnostic 
tool for the evaluation of syncope, and it is now thought that 
many patients with unexplained syncope have abnormal neu- 
rocardiac reflexes as the underlying mechanism ofsyncope (2). 
However, some investigators (12) have questioned the validity 
of the concept and the specificity of the testing procedure. To 
address these issues, we performed a large prospective study 
using head-up tilt testing as the primary diagnostic tool for the 
evaluation and management of syncope. Our analyses include 
the results of both acute intravenous and long-term oral 
beta-blocker therapy. Among the 193 patients who had a 
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positive test result, from the group of 296 consecutive patients 
studied, the response to the acute intravenous administration 
of the noncardioselective beta-blocker p opranolol was used to 
guide oral beta-blocker therapy, and oral drug efficacy was 
confirmed by both repeat head-up tilt testing during oral 
therapy and long-term clinical follow-up. 
Patient characteristics. The incidence of a positive tilt test 
result (65%) in our patients is similar to that reported by 
others (6,13). Few data have been provided on the character- 
istics of patients with a positive tilt test result. In this study, we 
found that such patients were significantly ounger and had 
significantly lower rest levels of heart rate and blood pressure, 
possibly reflecting a higher vagal tone at rest. A mixed vaso- 
depressor and eardioinhibitory esponse was the most common 
hemodynamie r sponse; however, patients with a pure vasode- 
pressor esponse were significantly older, possibly suggesting 
that lack of appropriate sympathetically mediated peripheral 
vasoconstriction is a factor in older patients with neurocardio- 
genie syncope. 
Use of isoproterenol. The majority of patients (89%) in this 
study required isoproterenol challenge to elicit a positive test 
result. Similarly, Sheldon and Killam (14) reported that 66 of 
100 patients referred for unexplained syncope had a positive 
tilt test result and that >90% of these 66 had required 
isoproterenol to produce syncope or near syncope. In that 
study, >60% of patients who had a positive test result required 
a dose of 5 ~g/min of isoproterenol. In the present study, 35~ 
of patients required up to 2/~g/min of isoproterenol and 54c~f 
of patients required 5 ~tg/min to elicit a positive test result. In 
contrast, Sra et al. (5) reported that only 12 (35%) of 34 
patients required isoproterenol to elicit a positive test result, 
whereas Waxman et al. (3) reported that 12 (60%) of 20 
patients required isoproterenol. This discrepancy may be ex- 
plained by the variability inherent in smaller patient numbers 
or by selection bias. 
In a recent review, Kapoor et al. (15) analyzed five studies 
utilizing 80 ° tilt testing and isoproterenol challenge and found 
that 24 (34%) of 70 control subjects had a positive test result. 
Although a high incidence of false positive tests is a valid 
concern, this may not be a factor in our study because the 
recurrence of symptoms among patients not compliant with 
oral beta-blocker therapy proved effective by tilt testing was 
independent of the need for isoproterenol to elicit an initial 
positive test result. 
Responses to intravenous beta.blockade. Overall, 90% of 
our patients responded beneficially to acute administration of
intravenous propranolol and had a negative repeat tilt test 
result on the same day. The observation that acute intravenous 
administration of a beta-adrenergic blocker prevents the hy- 
potension or bradycardia, or both, that characterizes a positive 
head-up tilt test result has been made by other investigators 
(3,5,7) and reinforces the theory that an increase in adrenergic 
tone is an important riggering mechanism for episodes of 
neurocardiogenic syncope. In contrast o a 90% beneficial 
response rate to beta-blocker therapy in the present study, Sra 
et al. (5) reported that only 13 (507}) of 26 patients who had a 
positive tilt test result and underwent acute repeat ilt testing 
after intravenous metoprolol responded beneficially. We also 
observed that 9 (43%) of 21 patients who had a positive tilt test 
result without isoproterenol challenge responded beneficially 
to intravenous propranolol, indicating that beta-adrenergic 
blocker therapy is beneficial in patients who do not require 
beta-adrenergic stimulation for a positive test result. Similarly, 
Sra et al. (7) reported that 6 (35%) of 17 patients who had a 
positive tilt test result without isoproterenol challenge re- 
sponded beneficially to the short-acting cardioselective b ta- 
adrenergic blocker esmolol. The higher proportion of our 
patients responding to intravenous propranolol, with or with- 
out isoproterenol challenge during repeat ilt testing, may be 
explained by the fact that a nonselective beta-adrenergic 
blocker crosses the blood-brain barrier and thus may be more 
effective in the acute treatment of neurocardiogenic syncope. 
This suggests not only that cardiac and peripheral autonomic 
reflexes are important, but also that central nervous system 
reflexes may be involved. In selected patients, aprimary role of 
central nervous system mechanisms has been suggested and 
therefore penetration of the blood-brain barrier may be more 
important than previously realized. This concept is supported 
by the fact that valproic acid (16), an anticonvulsant agent, and 
fluoxetine hydrochloride, an antidepressant (17), have been 
shown to be effective in some patients with neurocardiogenic 
syncope. 
Another explanation of our greater success with beta- 
adrenergic blockers may be related to dose. In our study, doses 
of intravenous propranolol were based on total body weight 
rather than an empiric dose; thus, patients may have been 
subjected to more complete beta-adrenergic blockade. How- 
ever, 10% of patients in this study did not respond beneficially 
to acute administration of intravenous propranolol. In three 
patients, underlying conduction system disease interfered with 
administration of adequate doses of propranolol to achieve 
beta-adrenergic blockade; after pacemaker implantation full 
beta-blockade was achieved in these patients and their tilt test 
response converted from positive to negative with a combina- 
tion of beta-blocker and pacemaker therapy. Another possible 
explanation for lack of a beneficial response to acute intrave- 
nous propranolol therapy in some patients is drug-induced 
hypotension caused by overmedication with propranolol. This 
was a factor that at least one patient who responded benefi- 
cially to oral therapy but not to intravenous therapy. We did 
not specifically test for discordance between the response to 
oral and intravenous therapy in this study. 
Response to oral beta-blockade. It has been generally 
accepted that oral beta-adrenergie blocker therapy provides 
effective treatment for neurocardiogenic syncope, but the 
number of patients evaluated uring long-term follow-up is 
limited. We performed repeat head-up tilt testing on oral 
beta-blockers in 125 patients and the drug efficacy ranged from 
91% to 100% during repeat esting (Table 3). The type of oral 
beta-blocker therapy was not randomized in this study, but the 
cardioselective and noncardioseleetive agents had similar effi- 
cacies. Oral beta-blocker therapy significantly decreased the 
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rest values of systolic blood pressure and heart rate from 
pretreatment values. 
Recurrence of syncope. During a mean long-term follow- 
up period of 28 _+ 11 months, 90% of patients remained 
symptom free on beta-blocker therapy guided by tilt testing. 
When repeat tilt testing was not used to guide beta-blocker 
therapy, 77% of patients remained symptom flee. In contrast, 
patients with a positive tilt test result who responded benefi- 
cially to oral beta-blocker therapy during repeat ilt testing but 
discontinued therapy had a high (42%) recurrence rate. Sim- 
ilarly, in patients who did not undergo repeat tilt testing or 
receive empiric beta-blocker therapy, the recurrence of syn- 
cope was 58%, indicating that the majority of patients with 
neurocardiogenic syncope benefit from beta-blocker therapy. 
Our results are similar to those of Natale et al. (11), who 
demonstrated that tilt test-guided therapy was most effective 
and yielded a 6% recurrence rate of symptoms among 234 
patients, 145 of whom were receiving beta-blocker therapy. 
Empiric therapy in their study provided a 30% rate of recur- 
rence of symptoms and patients without therapy had a 67%, 
recurrence rate. In our study the recurrence rate of syncope 
was 16% among patients who had a negative tilt test result at 
initial evaluation. Forty-eight percent of these patients had an 
identifiable cause of syncope that could be treated. 
Conclusions. In a large cohort of patients undergoing 
head-up tilt testing, 65% of patients referred because of 
unexplained syncope or near syncope had a positive head-up 
tilt test result and intravenous propranolol proved very effec- 
tive in blocking the abnormal neurocardiac reflex during 
head-up tilt testing. Patients with a positive head-up tilt test 
result are younger and have significantly lower rest values for 
heart rate and blood pressure than do patients who have a 
negative tilt test result, suggesting a higher vagal tone at rest in 
patients with a positive result. In addition, the response to 
intravenous propranolol accurately predicts the response to 
oral beta-blockers, either selective or noncardioselective, in 
90% of the patients. Beta-blockers are generally well tolerated 
during long-term therapy, and the recurrence of syncope is 
lowest (10%) in patients who remain on therapy guided by tilt 
testing. Beta-blocker treatment is slightly less effective when 
not guided by tilt testing. The rate of recurrence of syncope is 
high (42%-58%) in patients who discontinue therapy, indicat- 
ing that beta blockers are clearly beneficial. In patients with a 
negative tilt test result, the recurrence rate of syncope is 16%. 
We are grateful to Maria A. Hernandez and Shirley Delgado for assistance in the 
preparation fthe manuscript and to Kenneth M. Kessler, MD, FACC for review 
of the manuscript. 
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